In the first head-to-head comparison of leading incretin-based therapies, Eli Lilly’s dual GIP/GLP-1 receptor agonist ...

A phase 1 trial has initiated and is investigating treatment with ziftomenib plus Gleevec in advanced GIST following ...

Virgo Surgical Video Solutions, Inc., a leader in endoscopic AI technologies, today announced the official launch of EndoML ...

In the Phase 2 open-label study, REC-4881 (4 mg QD) led to a median 43% reduction (n=6 patients) in polyp burden at the Week ...

In April 2025, our partner Jazz announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of ...

Diarrhea Diarrhea was the most common adverse reaction in two randomized, double-blind, placebo-controlled trials of IBS-C. Severe diarrhea was reported in 2.5% of IBSRELA-treated patients. If severe ...

Q1 2025 Earnings Conference Call May 9, 2025 10:00 AM ETCompany ParticipantsJustine Koenigsberg - Vice President ...

Q1 2025 Earnings Call Transcript May 8, 2025 John Menditto – VP of IR and Corporate Communications: David Mazzo – President and CEO: James Nisco – SVP of Finance and Treasury and Chief Accounting ...

Six posters presented at the American Association for Cancer Research (AACR) annual meetingAppointment of Dr. Sabeen Mekan as Senior Vice President, Clinical DevelopmentReported $321.6 million in cash ...

Phase 1 dose-escalation study to evaluate ziftomenib in combination with imatinib in patients with advanced GIST after imatinib failure – – Combination of ziftomenib and imatinib shows robust and ...

Foxit, a leading provider of innovative PDF and eSignature products and services, helping knowledge workers to increase their productivity and do more with documents, today announced a significant ...